Cuba executes phase III clinical trial of drug for ataxia type two.
A phase III clinical trial to evaluate the efficacy and safety of the nasal administration of NeuroEPO in adult patients with spinocerebellar ataxias is successfully developed in Cuba.
Cuba is the country in the world with the highest prevalence of Ataxia type sca2, at a rate of 36.2 cases per 100,000 inhabitants, although its frequency in the province of Holguin is 183 cases per 100,000 individuals, Granma newspaper reported.
Internationally, the incidence of this type of ataxia is three to five cases per 100,000 people.




